![The Nobel Prize: In 1975 Georges Köhler and Cesar Milstein developed a method to fuse a normal antibody-producing cell with a tumour cell, forming a hybrid that was both immortal and could create a specific antibody](https://oncodaily.com/pub/uploads/2024/04/image-29.png)
The Nobel Prize: In 1975 Georges Köhler and Cesar Milstein developed a method to fuse a normal antibody-producing cell with a tumour cell, forming a hybrid that was both immortal and could create a specific antibody
Source: The Nobel Prize/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
The Nobel Prize shared on LinkedIn:
“Did you know that we have millions of different antibodies, but each white blood cell in our immune system produces only one kind of antibody?
In 1975 Georges Köhler and Cesar Milstein developed a method to fuse a normal antibody-producing cell with a tumour cell, forming a hybrid that was both immortal and could create a specific antibody. Their hybrid cell could produce antibodies of the same type – monoclonal antibodies – in whatever quantities are needed for research and medicine.
The production of monoclonal antibodies has enabled researchers to improve tests for infectious diseases, design completely new therapeutic strategies for diseases such as cancer, better explain the mechanisms behind autoimmune diseases and suppress rejection in organ transplants among other breakthroughs.
While the market for monoclonal antibodies is now worth billions of dollars, Köhler and Milstein did not patent their technique or benefit financially by forming a company, instead remaining in research.
Köhler shared the 1983 Nobel Prize in Physiology or Medicine with Niels K. Jerne and César Milstein. Learn more about their work.
Image: Anti-Cancer Antibodies. Small chemical ornaments (cones) slow the release of anti-cancer antibodies (blue) from this functionalised mesoporous silica (orange).”